Orexo AB (FRA:C5G) Cyclically Adjusted FCF per Share: €-0.08 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C5G Orexo AB FRA:C5G
43 GF Score
Price €1.35
GF Value €0.33
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Cyclically Adjusted FCF per Share?

Orexo AB FRA:C5G -14.45% 43 Cyclically Adjusted FCF per Share is €-0.08 as of Jun. 2026. GuruFocus rates FRA:C5G with a GF Score™ of 43/100 and a GF Value™ of €0.33 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Orexo AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.219. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.08 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 51.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 31.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Orexo AB was 51.00% per year. The lowest was -27.20% per year. And the median was 21.40% per year.

As of today (2026-07-20), Orexo AB's current stock price is €1.35. Orexo AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.08. Orexo AB's Cyclically Adjusted Price-to-FCF of today is .


Orexo AB  (FRA:C5G) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Orexo AB Cyclically Adjusted FCF per Share Related Terms


Orexo AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Orexo AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Cyclically Adjusted FCF per Share Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.29 -0.20 -0.04 -0.03

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.03 -0.03 -0.05 -0.08

FRA:C5G vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orexo AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:C5G
43GF Score
Orexo AB FRA:C5G
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orexo AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.219/134.1100*134.1100
=-0.219

Current CPI (Jun. 2026) = 134.1100.

Orexo AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.091 101.138 0.121
201612 0.212 102.022 0.279
201703 0.085 102.022 0.112
201706 0.144 102.752 0.188
201709 0.277 103.279 0.360
201712 -0.069 103.793 -0.089
201803 0.302 103.962 0.390
201806 0.105 104.875 0.134
201809 0.065 105.679 0.082
201812 0.196 105.912 0.248
201903 0.137 105.886 0.174
201906 0.118 106.742 0.148
201909 0.323 107.214 0.404
201912 0.104 107.766 0.129
202003 0.115 106.563 0.145
202006 -0.313 107.498 -0.390
202009 -0.174 107.635 -0.217
202012 -0.118 108.296 -0.146
202103 -0.184 108.360 -0.228
202106 -0.098 108.928 -0.121
202109 -0.288 110.338 -0.350
202112 -0.236 112.486 -0.281
202203 -0.187 114.825 -0.218
202206 0.027 118.384 0.031
202209 -0.168 122.296 -0.184
202212 -0.161 126.365 -0.171
202303 -0.162 127.042 -0.171
202306 -0.059 129.407 -0.061
202309 -0.070 130.224 -0.072
202312 -0.009 131.912 -0.009
202403 -0.052 132.205 -0.053
202406 -0.024 132.716 -0.024
202409 -0.034 132.304 -0.034
202412 -0.228 132.987 -0.230
202503 -0.110 132.825 -0.111
202506 -0.125 133.699 -0.125
202509 -0.023 133.480 -0.023
202512 -0.062 133.390 -0.062
202603 -0.078 133.560 -0.078
202606 -0.219 134.110 -0.219

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.08 mean?
Orexo AB (FRA:C5G) has a Cyclically Adjusted FCF per Share of €-0.08 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orexo AB and its competitors.
Is Orexo AB's Cyclically Adjusted FCF per Share too high?
Orexo AB's current Cyclically Adjusted FCF per Share is €-0.08. Overall, Orexo AB has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Orexo AB's Cyclically Adjusted FCF per Share of €-0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orexo AB and its competitors. Orexo AB's current Cyclically Adjusted FCF per Share is €-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (FRA:C5G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.33, compared to a current price of €1.35 — trading 309.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.08. Orexo AB's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Orexo AB (FRA:C5G), the current Cyclically Adjusted FCF per Share is €-0.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (FRA:C5G) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of €1.35 is trading 309.1% above its estimated GF Value™ of €0.33. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for FRA:C5G:

  • Cyclically Adjusted FCF per Share: €-0.08
  • GF Value™: €0.33 vs. price of €1.35 (309.1% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the FRA:C5G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
43GF Score

Get the complete analysis for FRA:C5G

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.35
Price
€0.33
GF Value